• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis

by | Sep 18, 2024 | Publications

Hematology. 2024 Dec;29(1):2399430. doi: 10.1080/16078454.2024.2399430. Epub 2024 Sep 9. ABSTRACT BACKGROUND: Renal insufficiency (RI) is a key factor affecting the prognosis of multiple myeloma (MM) patients. Because the benefit of daratumumab for treating MM...

Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: a critical appraisal of the pre-antibody era

by | Sep 18, 2024 | Publications

Clin Exp Med. 2024 Sep 9;24(1):215. doi: 10.1007/s10238-024-01481-2. ABSTRACT The benefit of high-dose melphalan followed by autologous hematopoietic stem cell transplantation (HDM-ASCT) for multiple myeloma (MM) patients with renal insufficiency (RI) is debated. A...

Meta-analysis of effectiveness and safety of proteasome inhibitor-dependent maintenance treatment for multiple myeloma a systematic review

by | Sep 18, 2024 | Publications

Heliyon. 2024 Aug 13;10(16):e36311. doi: 10.1016/j.heliyon.2024.e36311. eCollection 2024 Aug 30. ABSTRACT BACKGROUND: Even with significant advancements, treating multiple myeloma (MM) remains difficult. At present, the main treatment methods include combined...

Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients

by | Sep 18, 2024 | Publications

Clin Cancer Res. 2024 Sep 11. doi: 10.1158/1078-0432.CCR-24-1798. Online ahead of print. ABSTRACT PURPOSE: CAR T-cell therapy is a potent immunotherapy for hematologic malignancies, but patients can develop long-term adverse events including second primary...

The acceptability of using wearable electronic devices to monitor physical activity of patients with Multiple Myeloma undergoing treatment: a systematic review

by | Sep 18, 2024 | Publications

Clin Hematol Int. 2024 Jul 29;6(3):38-53. doi: 10.46989/001c.121406. eCollection 2024. ABSTRACT INTRODUCTION: Multiple myeloma (MM) is diagnosed in 6,000 people in the UK yearly. A performance status measure, based on the patients’ reported level of physical...

Role of Autologous Transplant in Newly Diagnosed Multiple Myeloma Patients Treated with Novel Triplets: A Systematic Review and Meta-Analysis

by | Sep 18, 2024 | Publications

Acta Haematol. 2024 Sep 16:1-17. doi: 10.1159/000540232. Online ahead of print. ABSTRACT INTRODUCTION: High-dose therapy with melphalan followed by autologous stem cell transplant at the upfront setting (upfront ASCT) has significantly improved clinical outcomes of...
« Older Entries
Next Entries »

Recent Content

  • Associations Between Patient Characteristics and Progression to Multiple Myeloma Among Patients With Monoclonal Gammopathy of Undetermined Significance: A Systematic Review
  • ASH 2024: Cilta-Cel Achieves Sustained MRD Negativity in Patients With Multiple Myeloma
  • Emerging BCMA-Directed Therapies in Multiple Myeloma: Bispecific Antibodies and CAR T-Cell Therapies
  • Advancements in Multiple Myeloma Therapies and Operational Insights in Oncology Clinical Trials
  • Darzalex Regimen May Improve MRD Responses in Multiple Myeloma
  • Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
  • Hexamethylene amiloride induces lysosome-mediated cell death in multiple myeloma through transcription factor E3
  • Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study
  • Black Patients With Myeloma Face Taste, Skin Side Effects from Talvey
  • ASH 2024: Expert Discusses Challenges, Future Research Opportunities With Bispecific Antibodies in Multiple Myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT